Looking Ahead: Where the BPH Space Is Going

In this video, C. Shawn West, MD, a urologist with McIver Urological Clinic in Florida, reflects on the future direction of benign prostatic hyperplasia (BPH) management within the expanding minimally invasive landscape. He notes that although reimbursement considerations may influence site of service, they should not alter clinical decision-making or the selection of the most appropriate therapy for a given patient.

West said he anticipates continued growth in the adoption of minimally invasive therapies, driven by patient demand, technological innovation, and increasing awareness among referring providers. He stresses the importance of earlier intervention to preserve bladder function and improve long-term outcomes, cautioning against prolonged reliance on medical therapy in patients with progressive symptoms.

Looking ahead, West calls for ongoing education among urologists and advanced practice providers to keep pace with emerging technologies and evolving evidence. He emphasizes transparency, shared decision-making, and individualized care as foundational principles in navigating this increasingly complex treatment landscape, ensuring that patients receive optimal, evidence-based management tailored to their needs.